Intra-Cellular Therapies, Inc. (ITCI) — Financial statements
Income statement, balance sheet, and cash flow for Intra-Cellular Therapies, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 681↑46.6% | 464↑86.4% | 249↑204.9% | 82↑262.7% | 23 | |
| Cost of Revenue | 57↑68.8% | 34↑65.1% | 20↑154.4% | 8↑324.0% | 2 | |
| Gross Profit | 624↑44.9% | 431↑88.3% | 229↑210.4% | 74↑257.0% | 21 | |
| Operating Expenses | ||||||
| R&D Expenses | 236↑31.1% | 180↑33.7% | 135↑51.6% | 89↑35.1% | 66 | |
| General & Administrative Expenses | 0.00↓100.0% | 318↑16.4% | 273↑43.6% | 190↑26.7% | 150 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 92↑7.5% | 86↑4.0% | 83↑127.3% | 36 | |
| SG&A Expenses | 504↑23.1% | 410↑14.2% | 359↑31.6% | 273↑46.3% | 186 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -1↑43.6% | -2↓642.4% | -0.28 | |
| Operating Expenses | 741↑25.5% | 590↑19.8% | 492↑37.0% | 359↑42.7% | 252 | |
| Total Costs & Expenses | 798↑27.9% | 624↑21.6% | 513↑39.6% | 367↑44.8% | 254 | |
| Operating Results | ||||||
| Operating Income | -117↑26.8% | -159↑39.5% | -264↑7.7% | -286↓23.6% | -231 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.53↓19.5% | 0.66↑23.0% | 0.53↑1.0% | 0.53 | |
| EBITDA | -117↑26.5% | -159↑39.6% | -263↑7.8% | -285↓23.6% | -231 | |
| EBIT | -117↑26.8% | -159↑39.5% | -264↑7.7% | -286↓23.6% | -231 | |
| Interest & Other Income | ||||||
| Net Interest Income | 43↑109.0% | 20↑175.8% | 7↑370.4% | 2↓63.0% | 4 | |
| Interest Income | 43↑109.0% | 20↑175.8% | 7↑370.4% | 2↓63.0% | 4 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 43↑109.0% | 20↑175.8% | 7↑370.5% | 2↓63.0% | 4 | |
| Income Before Tax | -74↑46.6% | -139↑45.7% | -256↑9.8% | -284↓25.2% | -227 | |
| Income Tax Expense | 0.47↓25.6% | 0.64↑10500.0% | 0.01↑6.6% | 0.01↓58.3% | 0.01 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -75↑46.5% | -140↑45.5% | -256↑9.8% | -284↓25.2% | -227 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -75↑46.5% | -140↑45.5% | -256↑9.8% | -284↓25.2% | -227 | |
| Bottom-Line Net Income | -75↑46.5% | -140↑45.5% | -256↑9.8% | -284↓25.2% | -227 | |
| EPS (Basic) | -0.72↑50.7% | -1.46↑46.3% | -2.72↑22.3% | -3.50↓8.4% | -3.23 | |
| EPS (Diluted) | -0.72↑50.7% | -1.46↑46.3% | -2.72↑22.3% | -3.50↓8.4% | -3.23 | |
| Weighted Average Shares | 103↑7.6% | 96↑2.0% | 94↑15.7% | 81↑15.5% | 70 | |
| Weighted Average Diluted Shares | 103↑7.6% | 96↑2.0% | 94↑15.7% | 81↑15.5% | 70 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.